New hope for hepatitis d: libevitug enters final testing phase
NCT ID NCT07499544
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing a new drug called libevitug in 160 people with chronic hepatitis D, a serious liver infection. The goal is to see if libevitug can lower the virus in the blood and improve liver health. Participants receive the drug by IV infusion, and the study compares different doses to find the best approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
libevitug
What this could lead to
If it works, this could offer a new treatment option to control chronic hepatitis D, reducing virus levels and improving liver function.
What could go wrong
This is an early Phase 3 trial with only 160 participants. The drug may not work for everyone, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chronic Hepatitis B/D Trial: P1101 + Anti-PD1 (NCT04638439)
- Hepatitis D Antibody Trial (NCT07610772)
- Brelovitug for Hepatitis Delta: Phase 3 Trial NCT07298330
- Bulevirtide PK in Liver Impairment Study | NCT05765344
- Bulevirtide for Chronic Hepatitis D – NCT05718700
- AZURE-1 Trial: BJT-778 for Chronic Hepatitis Del NCT06907290
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130033, China